Wedbush Lowers Fair Value on ARYx Therapeutics (ARYX); New Equity and Debt Arrangements Extend Cash Runway to End of 2010
Tweet Send to a Friend
Wedbush maintains an 'Outperform' rating on ARYx Therapeutics, Inc. (Nasdaq: ARYX), lowers PT from $4 to $1.50.
Wedbush analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
